Wie hoch ist der Preis für Spectrum Pharmaceuticals, Inc. (SPPI)

Preis für Spectrum Pharmaceuticals, Inc. (SPPI) ist $1.03

Wie hoch ist die Marktkapitalisierung für Spectrum Pharmaceuticals, Inc. (SPPI)

Marktkapitalisierung für Spectrum Pharmaceuticals, Inc. (SPPI) ist $115.13M

Spectrum Pharmaceuticals, Inc. (SPPI) Aktiensplits

Spectrum Pharmaceuticals, Inc. operates as a biopharmaceutical firm, primarily engaged in the research, development, and market introduction of innovative drug products for cancer and blood disorders. Its robust pipeline features Eflapegrastim, an advanced, long-acting granulocyte colony-stimulating factor designed to address chemotherapy-induced neutropenia. Also under development is Poziotinib, a distinct irreversible tyrosine kinase inhibitor intended for non-small cell lung cancer tumors exhibiting various mutations. Furthermore, Anti-CD20-IFNa, an antibody-interferon fusion molecule targeting CD20, is progressing through Phase I development for patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. The company maintains key collaborative agreements, such as co-development, commercialization, and in-licensing arrangements with Hanmi Pharmaceutical Co. Ltd., a patent and technology license with The University of Texas M.D. Anderson Cancer Center, and an in-license pact with ImmunGene, Inc. Founded in 1987, and initially known as NeoTherapeutics, Inc. before its name change in December 2002, Spectrum Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.